Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06979453 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
A Phase 3 study of Plaque Psoriasis, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 366
- Enrollment target
- 20
- Study locations
NCT06979453: Recruiting Phase 3 study of Plaque Psoriasis, sponsored by Bristol-Myers Squibb.
NCT06979453 is a Phase 3 study of Plaque Psoriasis that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 366 participants, below the 408-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (10% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06979453, a Phase 3 study of Plaque Psoriasis, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 366 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy, safety, and drug levels of Deucravacitinib (BMS-986165) in adolescent participants with moderate to severe plaque psoriasis
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Deucravacitinib
Study Locations (20)
California
- Local Institution - 0025 - Fountain Valley
- Center For Dermatology Clinical Research, Inc. - Fremont
- Dermatology Research Associates - Los Angeles
- Northridge Clinical Trials - Northridge
- Local Institution - 0077 - Sacramento
- Golden State Dermatology - Walnut Creek - Ygnacio Valley Road - Walnut Creek
Florida
- Local Institution - 0021 - Clearwater
- Life Clinical Trials - Margate
- Skin Research of South Florida - Miami
- Wellness Clinical Research - Miami Lakes
- Palm Harbor Dermatology PA d/b/a TrueBlue Clinical Research - Tampa
Alabama
- Local Institution - 0261 - Birmingham
- Local Institution - 0041 - Birmingham
Georgia
- Dermatology Affiliates Research Institute - Atlanta
- Advanced Medical Research, PC. - Sandy Springs
Arizona
- Local Institution - 0053 - Phoenix
Colorado
- Paradigm Clinical Research, LLC - Wheat Ridge
Indiana
- Dawes Fretzin Clinical Research Group, LLC - Indianapolis
Kentucky
- Local Institution - 0262 - Murray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 366 participants |
| Start Date | 2025-12-03 |
| Est. Completion | 2034-08-12 |
| Phase | Phase 3 |
What NCT06979453 shows while recruiting
NCT06979453 is an interventional study that assigns participants to a tested intervention. The registered 366 participants enrollment target is mid-sized for trials with a published cap, below the 408-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (10% lower).
The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06979453 names 20 study sites across 9 states, led by California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT06979453 about?
NCT06979453 is a clinical study titled "A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis". The purpose of this study is to evaluate the efficacy, safety, and drug levels of Deucravacitinib (BMS-986165) in adolescent participants with moderate to severe plaque psoriasis
What is the current status of trial NCT06979453?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 366 participants. The study started on 2025-12-03. Estimated completion is 2034-08-12.
What conditions does trial NCT06979453 study?
This clinical trial studies the following conditions: Plaque Psoriasis.
What interventions are being tested in trial NCT06979453?
The interventions under investigation include: Placebo (OTHER), Deucravacitinib (DRUG).
Who is sponsoring clinical trial NCT06979453?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06979453 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06979453's enrollment target sits among peer trials
366 13th of 45 higher than 33 of 45 other Plaque Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Plaque Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
RECRUITING · Phase 3
-
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
RECRUITING · Phase 3
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
ACTIVE NOT RECRUITING · Phase 3
-
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
ACTIVE NOT RECRUITING · Phase 3
-
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05083481 · 366 participants · Phase 1
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
- NCT05429632 · 366 participants · Phase 3
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
- NCT04049604 · 365 participants · NA
IDENTIFY Study: Natural History of Maternal Neoplasia
- NCT05065840 · 365 participants · NA
Advancing HPV Vaccination Among HIV Positive Adults: The CHAMPS Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI